Research & Development Market Research Reports & Industry Analysis
New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.
Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.
Research & Development Industry Research & Market Reports
-
Acute Heart Failure (AHF) Therapeutics
... is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 21.3% over the analysis period 2023-2030. Cardiac Glycosides, one of the segments analyzed in the report, is expected to record a 21.8% ... Read More
-
Pharmaceutical Contract Manufacturing
... by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. API/Bulk Drugs, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$94.8 Billion by ... Read More
-
Osteoporosis Therapeutics
... at a CAGR of 2.8% over the analysis period 2023-2030. Bisphosphonates Drug Class, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$8.1 Billion by the end ... Read More
-
Drug Discovery Technologies
... by 2030, growing at a CAGR of 8.7% over the analysis period 2023-2030. Small Molecule Drugs Discovery Technologies, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach ... Read More
-
Antibacterial Drugs
... at a CAGR of 3.9% over the analysis period 2023-2030. ß-lactams Drug Class, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end ... Read More
-
Testosterone Replacement Therapy (TRT)
... reach US$2.5 Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2023-2030. TRT Topicals, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach ... Read More
-
Cannabis Beverages
... at a CAGR of 16.4% over the analysis period 2023-2030. Non-Alcoholic Beverage, one of the segments analyzed in the report, is expected to record a 16.9% CAGR and reach US$2.0 Billion by the end of ... Read More
-
Fibromyalgia Therapeutics
... at a CAGR of 3.0% over the analysis period 2023-2030. Antiepileptics Drug Class, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$2.1 Billion by the end ... Read More
-
Melanoma Therapeutics
... at a CAGR of 13.8% over the analysis period 2023-2030. Cutaneous Melanoma Therapeutics, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$4.3 Billion by the end ... Read More
-
Anemia Drugs
... at a CAGR of 4.1% over the analysis period 2023-2030. Iron Deficiency Anemia Drugs, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the ... Read More
-
Lymphoma Therapeutics
... at a CAGR of 6.6% over the analysis period 2023-2030. Non-Hodgkin Lymphoma (NHL) Therapeutics, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$20.5 Billion by the ... Read More
-
Cancer Therapies
... at a CAGR of 10.4% over the analysis period 2023-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$112.8 Billion by the end of the ... Read More
-
Colorectal Cancer Therapeutics
... by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by ... Read More
-
HIV Drugs
... at a CAGR of 5.3% over the analysis period 2023-2030. Combination HIV Medicines, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$29.0 Billion by the end ... Read More
-
mRNA Platform
... at a CAGR of -3.1% over the analysis period 2023-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.1% CAGR and reach US$96.5 Billion by the end of ... Read More
-
Pharma And Biotech CRM Software Global Market Report 2024
... And Medium Enterprise (SMEs)4) By Industry: Pharmaceuticals; BiotechCovering: Oracle Corporation; Salesforce.com Inc.; IQVIA Holdings Inc.; Trueblue Inc.; Cirrius Solutions Inc. Pharma And Biotech CRM Software Global Market Report 2024 from The Business Research Company provides ... Read More
-
Rheumatoid Arthritis Diagnosis Tests
... reach US$944.9 Million by 2030, growing at a CAGR of 5.3% over the analysis period 2023-2030. Diagnostic Laboratories End-Use, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and ... Read More
-
Pancreatic Cancer Drugs
... by 2030, growing at a CAGR of 4.7% over the analysis period 2023-2030. Exocrine Drugs, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.2 Billion by ... Read More
-
e-Clinical Trial Technologies
... by 2030, growing at a CAGR of 13.1% over the analysis period 2023-2030. Clinical Trial Management Systems (CTMS), one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach ... Read More
-
Nanocatalysts
... of 7.5% over the analysis period 2023-2030. Refinery & Petrochemicals Application, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.9 Billion by the end of the ... Read More
-
Contract Research Outsourcing
... by 2030, growing at a CAGR of 7.9% over the analysis period 2023-2030. Clinical Research Services, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$61.2 Billion ... Read More
-
Lung Cancer Therapeutics
... by 2030, growing at a CAGR of 10.9% over the analysis period 2023-2030. Non-Small-Cell Lung Cancer (NSCLC) Therapeutics, one of the segments analyzed in the report, is expected to record a 12.0% CAGR and reach ... Read More
-
Rheumatoid Arthritis Therapeutics
... by 2030, growing at a CAGR of 4.1% over the analysis period 2023-2030. Pharmaceuticals Molecule, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$28.0 Billion by ... Read More
-
Contract Research Organization Services (CROs)
... is expected to reach US$149.1 Billion by 2030, growing at a CAGR of 10.7% over the analysis period 2023-2030. Clinical Research Services, one of the segments analyzed in the report, is expected to record a ... Read More
-
Quantum Computing in Healthcare
... reach US$845.4 Million by 2030, growing at a CAGR of 37.4% over the analysis period 2023-2030. Quantum Computing in Healthcare Services, one of the segments analyzed in the report, is expected to record a 40.6% ... Read More
Research Assistance
